US refuses to compel lower prices for Pfizer and Astellas cancer drug
23-03-2023
NIH COVID-19 deal broadens access for poorer nations
19-05-2022
wavebreakmedia / Shutterstock.com
The US National Institutes of Health (NIH) has decided not to exercise its “march in-rights” for the Xtandi (enzalutamide) prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
National Institutes of Health, Astellas Pharma, Xtandi, enzalutamide, Francis Collins, Bayh-Dole Act, patent, march-in rights, patent
